nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.06.2013 | NON-THEMATIC REVIEW

Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

verfasst von: Cindy Neuzillet, Pascal Hammel, Annemilaï Tijeras-Raballand, Anne Couvelard, Eric Raymond

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1-2/2013

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic ductal adenocarcinoma (PAC) stands as the poorest prognostic tumor of the digestive tract with limited therapeutic options. PAC carcinogenesis is associated with the loss of function of tumor suppressor genes such as INK4A, TP53, BRCA2, and DPC4, and only a few activated oncogenes among which K-RAS mutations are the most prevalent. The K-RAS mutation occurs early in PAC carcinogenesis, driving downstream activation of MEK and ERK1/2 which promote survival, invasion, and migration of cancer cells. In PAC models, inhibition of members of the Ras–ERK pathway blocks cellular proliferation and metastasis development. As oncogenic Ras does not appear to be a suitable drug target, inhibitors targeting downstream kinases including Raf and MEK have been developed and are currently under evaluation in clinical trials. In this review, we describe the role of the Ras–ERK pathway in pancreatic carcinogenesis and as a new therapeutic target for the treatment of PAC.

Nur mit Berechtigung zugänglich

Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60(5), 277–300. doi:10.3322/caac.20073.CrossRef

Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. doi:10.1002/ijc.25516.

Hidalgo, M. (2010). Pancreatic cancer. The New England Journal of Medicine, 362(17), 1605–1617. doi:10.1056/NEJMra0901557.PubMedCrossRef

Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011). Pancreatic cancer. Lancet, 378(9791), 607–620. doi:10.1016/S0140-6736(10)62307-0.PubMedCrossRef

Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15(6), 2403–2413.PubMed

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25(15), 1960–1966. doi:10.1200/JCO.2006.07.9525.PubMedCrossRef

Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine, 364(19), 1817–1825. doi:10.1056/NEJMoa1011923.PubMedCrossRef

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W., Chang, F., et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta, 1773(8), 1263–1284. doi:10.1016/j.bbamcr.2006.10.001.PubMedCrossRef

Preis, M., & Korc, M. (2010). Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biology & Therapy, 9(10), 754–763.CrossRef

10.

Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, S. (2007). Ras oncogenes and their downstream targets. Biochimica et Biophysica Acta, 1773(8), 1177–1195. doi:10.1016/j.bbamcr.2007.01.012.PubMedCrossRef

11.

Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., et al. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget, 2(3), 135–164.PubMed

12.

Ramos, J. W. (2008). The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. The International Journal of Biochemistry & Cell Biology, 40(12), 2707–2719. doi:10.1016/j.biocel.2008.04.009.CrossRef

13.

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326), 968–972. doi:10.1038/nature09627.PubMedCrossRef

14.

Coles, L. C., & Shaw, P. E. (2002). PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene, 21(14), 2236–2244. doi:10.1038/sj.onc.1205302.PubMedCrossRef

15.

Schafer, R., & Sers, C. (2011). RAS oncogene-mediated deregulation of the transcriptome: from molecular signature to function. Advances in Enzyme Regulation, 51(1), 126–136. doi:10.1016/j.advenzreg.2010.11.005.PubMedCrossRef

16.

Owens, D. M., & Keyse, S. M. (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene, 26(22), 3203–3213. doi:10.1038/sj.onc.1210412.PubMedCrossRef

17.

Calvo, F., Agudo-Ibanez, L., & Crespo, P. (2010). The Ras–ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. Bioessays, 32(5), 412–421. doi:10.1002/bies.200900155.PubMedCrossRef

18.

Roberts, P. J., & Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26(22), 3291–3310. doi:10.1038/sj.onc.1210422.PubMedCrossRef

19.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. doi:10.1016/j.cell.2011.02.013.PubMedCrossRef

20.

Roovers, K., & Assoian, R. K. (2000). Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays, 22(9), 818–826. doi:10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6.PubMedCrossRef

21.

Mirza, A. M., Gysin, S., Malek, N., Nakayama, K., Roberts, J. M., & McMahon, M. (2004). Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Molecular and Cellular Biology, 24(24), 10868–10881. doi:10.1128/MCB.24.24.10868-10881.2004.PubMedCrossRef

22.

Maurer, G., Tarkowski, B., & Baccarini, M. (2011). Raf kinases in cancer—roles and therapeutic opportunities. Oncogene, 30(32), 3477–3488. doi:10.1038/onc.2011.160 onc2011160.PubMedCrossRef

23.

Wang, S., Ghosh, R. N., & Chellappan, S. P. (1998). Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Molecular and Cellular Biology, 18(12), 7487–7498.PubMed

24.

Ballif, B. A., & Blenis, J. (2001). Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth & Differentiation, 12(8), 397–408.

25.

Balmanno, K., & Cook, S. J. (2009). Tumour cell survival signalling by the ERK1/2 pathway. Cell Death and Differentiation, 16(3), 368–377. doi:10.1038/cdd.2008.148.PubMedCrossRef

26.

Allan, L. A., Morrice, N., Brady, S., Magee, G., Pathak, S., & Clarke, P. R. (2003). Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nature Cell Biology, 5(7), 647–654. doi:10.1038/ncb1005 ncb1005.PubMedCrossRef

27.

Sahu, R. P., Batra, S., Kandala, P. K., Brown, T. L., & Srivastava, S. K. (2011). The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 67(2), 481–487. doi:10.1007/s00280-010-1463-1.PubMedCrossRef

28.

Maida, Y., Kyo, S., Kanaya, T., Wang, Z., Yatabe, N., Tanaka, M., et al. (2002). Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene, 21(26), 4071–4079. doi:10.1038/sj.onc.1205509.PubMedCrossRef

29.

Ellenrieder, V., Hendler, S. F., Boeck, W., Seufferlein, T., Menke, A., Ruhland, C., et al. (2001). Transforming growth factor beta1 treatment leads to an epithelial–mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Research, 61(10), 4222–4228.PubMed

30.

Cano, C. E., Motoo, Y., & Iovanna, J. L. (2010). Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. The Scientific World Journal, 10, 1947–1957. doi:10.1100/tsw.2010.183.CrossRef

31.

Viala, E., & Pouyssegur, J. (2004). Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Annals of the New York Academy of Sciences, 1030, 208–218. doi:10.1196/annals.1329.027.PubMedCrossRef

32.

Lim, J. H., Lee, E. S., You, H. J., Lee, J. W., Park, J. W., & Chun, Y. S. (2004). Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene, 23(58), 9427–9431. doi:10.1038/sj.onc.1208003.PubMedCrossRef

33.

Danovi, S. A., Wong, H. H., & Lemoine, N. R. (2008). Targeted therapies for pancreatic cancer. British Medical Bulletin, 87, 97–130. doi:10.1093/bmb/ldn027.PubMedCrossRef

34.

Wong, H. H., & Lemoine, N. R. (2009). Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nature Reviews. Gastroenterology & Hepatology, 6(7), 412–422. doi:10.1038/nrgastro.2009.89.CrossRef

35.

Lee, J., Jang, K. T., Ki, C. S., Lim, T., Park, Y. S., Lim, H. Y., et al. (2007). Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer, 109(8), 1561–1569. doi:10.1002/cncr.22559.PubMedCrossRef

36.

Luo, G., Long, J., Qiu, L., Liu, C., Xu, J., & Yu, X. (2011). Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. Pancreatology, 11(6), 595–600. doi:10.1159/000334465.PubMedCrossRef

37.

Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & Depinho, R. A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Development, 20(10), 1218–1249. doi:10.1101/gad.1415606.CrossRef

38.

Luttges, J., Schlehe, B., Menke, M. A., Vogel, I., Henne-Bruns, D., & Kloppel, G. (1999). The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer, 85(8), 1703–1710. doi:10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R.PubMedCrossRef

39.

Morris, J. P. T., Wang, S. C., & Hebrok, M. (2010). KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nature Reviews. Cancer, 10(10), 683–695. doi:10.1038/nrc2899.PubMedCrossRef

40.

Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S., & Horii, A. (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. American Journal of Pathology, 162(6), 1807–1815. doi:10.1016/S0002-9440(10)64315-5.PubMedCrossRef

41.

Delpu, Y., Hanoun, N., Lulka, H., Sicard, F., Selves, J., Buscail, L., et al. (2011). Genetic and epigenetic alterations in pancreatic carcinogenesis. Current Genomics, 12(1), 15–24. doi:10.2174/138920211794520132CG-12-15.PubMedCrossRef

42.

Matthaios, D., Zarogoulidis, P., Balgouranidou, I., Chatzaki, E., & Kakolyris, S. (2011). Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology, 81(3–4), 259–272. doi:10.1159/000334449.PubMedCrossRef

43.

Steele, C. W., Oien, K. A., McKay, C. J., & Jamieson, N. B. (2011). Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas, 40(8), 1165–1171. doi:10.1097/MPA.0b013e3182218ffb00006676-201111000-00002.PubMedCrossRef

44.

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321(5897), 1801–1806. doi:10.1126/science.1164368.PubMedCrossRef

45.

Mazur, P. K., & Siveke, J. T. (2011). Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut. doi:10.1136/gutjnl-2011-300756.

46.

Skoulidis, F., Cassidy, L. D., Pisupati, V., Jonasson, J. G., Bjarnason, H., Eyfjord, J. E., et al. (2010). Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell, 18(5), 499–509. doi:10.1016/j.ccr.2010.10.015.PubMedCrossRef

47.

Matsuzaki, K. (2011). Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis, 32(11), 1578–1588. doi:10.1093/carcin/bgr172.PubMedCrossRef

48.

Zhao, S., Venkatasubbarao, K., Lazor, J. W., Sperry, J., Jin, C., Cao, L., et al. (2008). Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Research, 68(11), 4221–4228. doi:10.1158/0008-5472.CAN-07-5123.PubMedCrossRef

49.

Bachet, J. B., Marechal, R., Demetter, P., Bonnetain, F., Couvelard, A., Svrcek, M., et al. (2012). Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Annals of Oncology. doi:10.1093/annonc/mdr617.

50.

Wagner, E. F., & Nebreda, A. R. (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews. Cancer, 9(8), 537–549. doi:10.1038/nrc2694.PubMedCrossRef

51.

Ding, X. Z., & Adrian, T. E. (2001). MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1. Biochemical and Biophysical Research Communications, 282(2), 447–453. doi:10.1006/bbrc.2001.4595 S0006-291X(01)94595-4.PubMedCrossRef

52.

Handra-Luca, A., Lesty, C., Hammel, P., Sauvanet, A., Rebours, V., Martin, A., et al. (2012). Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma. Pancreas, 41(3), 416–421. doi:10.1097/MPA.0b013e318238379d.PubMedCrossRef

53.

del Barco Barrantes, I., & Nebreda, A. R. (2012). Roles of p38 MAPKs in invasion and metastasis. Biochemical Society Transactions, 40(1), 79–84. doi:10.1042/BST20110676.PubMedCrossRef

54.

Duner, S., Lopatko Lindman, J., Ansari, D., Gundewar, C., & Andersson, R. (2010). Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology, 10(6), 673–681. doi:10.1159/000320711.PubMedCrossRef

55.

Jaster, R. (2004). Molecular regulation of pancreatic stellate cell function. Molecular Cancer, 3, 26. doi:10.1186/1476-4598-3-26.PubMedCrossRef

56.

Vasseur, S. T. R., Tournaire, R., & Iovanna, J. L. (2010). Hypoxia induced tumor metabolic switch contributes to pancreatic cancer aggressiveness. Cancers, 2(4), 2138–2152. doi:10.3390/cancers2042138.CrossRef

57.

Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews. Cancer, 8(8), 592–603. doi:10.1038/nrc2442.PubMedCrossRef

58.

Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., et al. (2004). Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. Journal of Clinical Oncology, 22(13), 2610–2616. doi:10.1200/JCO.2004.12.040 22/13/2610.PubMedCrossRef

59.

Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O’Reilly, E. M., Flynn, P. J., et al. (2010). Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. Journal of Clinical Oncology, 28(22), 3605–3610. doi:10.1200/JCO.2009.25.7550.PubMedCrossRef

60.

Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J. L., et al. (2009). Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 27(13), 2231–2237. doi:10.1200/JCO.2008.20.0238.PubMedCrossRef

61.

Graeven, U., Kremer, B., Sudhoff, T., Killing, B., Rojo, F., Weber, D., et al. (2006). Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. British Journal of Cancer, 94(9), 1293–1299. doi:10.1038/sj.bjc.6603083.PubMedCrossRef

62.

Safran, H., Iannitti, D., Ramanathan, R., Schwartz, J. D., Steinhoff, M., Nauman, C., et al. (2004). Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Investigation, 22(5), 706–712.PubMedCrossRef

63.

Fountzilas, G., Bobos, M., Kalogera-Fountzila, A., Xiros, N., Murray, S., Linardou, H., et al. (2008). Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Investigation, 26(8), 784–793. doi:10.1080/07357900801918611.PubMedCrossRef

64.

Ignatiadis, M., Polyzos, A., Stathopoulos, G. P., Tselepatiotis, E., Christophylakis, C., Kalbakis, K., et al. (2006). A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology, 71(3–4), 159–163. doi:10.1159/000106064.PubMedCrossRef

65.

Brell, J. M., Matin, K., Evans, T., Volkin, R. L., Kiefer, G. J., Schlesselman, J. J., et al. (2009). Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology, 76(4), 270–274. doi:10.1159/000206141.PubMedCrossRef

66.

Safran, H. M. T., Bahary, N., Whiting, S., Lopez, C. D., Sun, W., Charpentier, K., Shipley, J., Anderson, E., McNulty, B., Schumacher, A., Clark, A., Vakharia, J., Kennedy, T., & Sio, T. (2011). Lapatinib and gemcitabine for metastatic pancreatic cancer: a phase II study. American Journal of Clinical Oncology, 34(1), 50–52. doi:10.1097/COC.0b013e3181d26b01.CrossRef

67.

Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., et al. (2004). Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. Journal of Clinical Oncology, 22(8), 1430–1438. doi:10.1200/JCO.2004.10.112 JCO.2004.10.112.PubMedCrossRef

68.

Martin, N. E., Brunner, T. B., Kiel, K. D., DeLaney, T. F., Regine, W. F., Mohiuddin, M., et al. (2004). A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clinical Cancer Research, 10(16), 5447–5454. doi:10.1158/1078-0432.CCR-04-024810/16/5447.PubMedCrossRef

69.

Toubaji, A., Achtar, M., Provenzano, M., Herrin, V. E., Behrens, R., Hamilton, M., et al. (2008). Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunology, Immunotherapy, 57(9), 1413–1420. doi:10.1007/s00262-008-0477-6.PubMedCrossRef

70.

Alberts, S. R., Schroeder, M., Erlichman, C., Steen, P. D., Foster, N. R., Moore, D. F., Jr., et al. (2004). Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. Journal of Clinical Oncology, 22(24), 4944–4950. doi:10.1200/JCO.2004.05.034.PubMedCrossRef

71.

McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S., Ove, R., et al. (2009). Emerging Raf inhibitors. Expert Opinion on Emerging Drugs, 14(4), 633–648. doi:10.1517/14728210903232633.PubMedCrossRef

72.

Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., et al. (2012). Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs, 30(1), 382–386. doi:10.1007/s10637-010-9526-z.PubMedCrossRef

73.

El-Khoueiry, A. B., Ramanathan, R. K., Yang, D. Y., Zhang, W., Shibata, S., Wright, J. J., et al. (2012). A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Investigational New Drugs, 30(3), 1175–1183. doi:10.1007/s10637-011-9658-9.PubMedCrossRef

74.

Lang, S. A., Schachtschneider, P., Moser, C., Mori, A., Hackl, C., Gaumann, A., et al. (2008). Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Molecular Cancer Therapeutics, 7(11), 3509–3518. doi:10.1158/1535-7163.MCT-08-0373.PubMedCrossRef

75.

Sebolt-Leopold, J. S., & Herrera, R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Reviews. Cancer, 4(12), 937–947. doi:10.1038/nrc1503.PubMedCrossRef

76.

McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S., Ove, R., et al. (2010). Emerging MEK inhibitors. Expert Opinion on Emerging Drugs, 15(2), 203–223. doi:10.1517/14728210903282760.PubMedCrossRef

77.

Montagut, C., & Settleman, J. (2009). Targeting the RAF–MEK–ERK pathway in cancer therapy. Cancer Letters, 283(2), 125–134. doi:10.1016/j.canlet.2009.01.022.PubMedCrossRef

78.

Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology, 23(23), 5281–5293. doi:10.1200/JCO.2005.14.415.PubMedCrossRef

79.

Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. Journal of Clinical Oncology, 22(22), 4456–4462. doi:10.1200/JCO.2004.01.185.PubMedCrossRef

80.

LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., et al. (2010). Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clinical Cancer Research, 16(6), 1924–1937. doi:10.1158/1078-0432.CCR-09-1883.PubMedCrossRef

81.

Trujillo, J. I. (2011). MEK inhibitors: a patent review 2008–2010. Expert Opinion on Therapeutic Patents, 21(7), 1045–1069. doi:10.1517/13543776.2011.577068.PubMedCrossRef

82.

Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L., Ko, M., et al. (2009). PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. Journal of Ocular Pharmacology and Therapeutics, 25(6), 519–530. doi:10.1089/jop. 2009.0060.PubMedCrossRef

83.

Faivre, S., Ronot, M., Dreyer, C., Serrate, C., Hentic, O., Bouattour, M., et al. (2012). Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Targeted Oncology, 7(2), 127–133. doi:10.1007/s11523-012-0216-y.PubMedCrossRef

84.

Engelman, J. A., & Settleman, J. (2008). Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current Opinion in Genetics and Development, 18(1), 73–79. doi:10.1016/j.gde.2008.01.004.PubMedCrossRef

85.

Diep, C. H., Munoz, R. M., Choudhary, A., Von Hoff, D. D., & Han, H. (2011). Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clinical Cancer Research, 17(9), 2744–2756. doi:10.1158/1078-0432.CCR-10-2214.PubMedCrossRef

86.

Wang, H., Daouti, S., Li, W. H., Wen, Y., Rizzo, C., Higgins, B., et al. (2011). Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Research, 71(16), 5535–5545. doi:10.1158/0008-5472.CAN-10-4351.PubMedCrossRef

87.

Little, A. S., Balmanno, K., Sale, M. J., Smith, P. D., & Cook, S. J. (2012). Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochemical Society Transactions, 40(1), 73–78. doi:10.1042/BST20110647.PubMedCrossRef

88.

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439(7074), 358–362. doi:10.1038/nature04304.PubMedCrossRef

89.

Jing, J., Greshock, J., Holbrook, J. D., Gilmartin, A., Zhang, X., McNeil, E., et al. (2012). Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Molecular Cancer Therapeutics, 11(3), 720–729. doi:10.1158/1535-7163.MCT-11-0505.PubMedCrossRef

90.

Yip-Schneider, M. T., Lin, A., & Marshall, M. S. (2001). Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochemical and Biophysical Research Communications, 280(4), 992–997. doi:10.1006/bbrc.2001.4243S0006-291X(01)94243-3.PubMedCrossRef

91.

Yeh, J. J., Routh, E. D., Rubinas, T., Peacock, J., Martin, T. D., Shen, X. J., et al. (2009). KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Molecular Cancer Therapeutics, 8(4), 834–843. doi:10.1158/1535-7163.MCT-08-0972.PubMedCrossRef

92.

Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., et al. (2010). A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics, 3, 26. doi:10.1186/1755-8794-3-26.PubMedCrossRef

93.

Holt, S. V., Logie, A., Odedra, R., Heier, A., Heaton, S. P., Alferez, D., et al. (2012). The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. British Journal of Cancer, 106(5), 858–866. doi:10.1038/bjc.2012.8 bjc20128.PubMedCrossRef

94.

Urick, M. E., Chung, E. J., Shield, W. P., 3rd, Gerber, N., White, A., Sowers, A., et al. (2011). Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clinical Cancer Research, 17(15), 5038–5047. doi:10.1158/1078-0432.CCR-11-0358.PubMedCrossRef

95.

Zhao, Y., Shen, S., Guo, J., Chen, H., Greenblatt, D. Y., Kleeff, J., et al. (2006). Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. Journal of Surgical Research, 136(2), 325–335. doi:10.1016/j.jss.2006.06.031.PubMedCrossRef

96.

Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y. M., et al. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Research, 69(10), 4286–4293. doi:10.1158/0008-5472.CAN-08-4765.PubMedCrossRef

97.

Halilovic, E., She, Q. B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., et al. (2010). PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Research, 70(17), 6804–6814. doi:10.1158/0008-5472.CAN-10-0409.PubMedCrossRef

98.

Chang, Q., Chen, E., & Hedley, D. W. (2009). Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biology & Therapy, 8(20), 1893–1901.CrossRef

99.

Chang, Q., Chapman, M. S., Miner, J. N., & Hedley, D. W. (2010). Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer, 10, 515. doi:10.1186/1471-2407-10-515.PubMedCrossRef

100.

Hatzivassiliou, G., Liu, B., O’Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., et al. (2012). ERK inhibition overcomes acquired resistance to MEK inhibitors. Molecular Cancer Therapeutics, 11(5), 1143–1154. doi:10.1158/1535-7163.MCT-11-1010.PubMedCrossRef

Titel: Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
verfasst von: Cindy Neuzillet
Pascal Hammel
Annemilaï Tijeras-Raballand
Anne Couvelard
Eric Raymond
Publikationsdatum: 01.06.2013
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1-2/2013
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9396-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2013

Tumor dormancy and the neuroendocrine system: an undisclosed connection?

Hide and seek: tell-tale signs of breast cancer lurking in the blood

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications

Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis

Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie